1. Home
  2. AGX vs STOK Comparison

AGX vs STOK Comparison

Compare AGX & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AGX
  • STOK
  • Stock Information
  • Founded
  • AGX 1961
  • STOK 2014
  • Country
  • AGX United States
  • STOK United States
  • Employees
  • AGX N/A
  • STOK N/A
  • Industry
  • AGX Engineering & Construction
  • STOK Biotechnology: Pharmaceutical Preparations
  • Sector
  • AGX Consumer Discretionary
  • STOK Health Care
  • Exchange
  • AGX Nasdaq
  • STOK Nasdaq
  • Market Cap
  • AGX 2.1B
  • STOK 638.8M
  • IPO Year
  • AGX N/A
  • STOK 2019
  • Fundamental
  • Price
  • AGX $202.51
  • STOK $12.10
  • Analyst Decision
  • AGX Buy
  • STOK Strong Buy
  • Analyst Count
  • AGX 2
  • STOK 5
  • Target Price
  • AGX $193.00
  • STOK $24.50
  • AVG Volume (30 Days)
  • AGX 477.1K
  • STOK 527.0K
  • Earning Date
  • AGX 06-04-2025
  • STOK 08-06-2025
  • Dividend Yield
  • AGX 0.74%
  • STOK N/A
  • EPS Growth
  • AGX 154.06
  • STOK N/A
  • EPS
  • AGX 7.14
  • STOK 0.88
  • Revenue
  • AGX $910,157,000.00
  • STOK $190,908,000.00
  • Revenue This Year
  • AGX $10.87
  • STOK $378.84
  • Revenue Next Year
  • AGX $18.35
  • STOK N/A
  • P/E Ratio
  • AGX $28.37
  • STOK $13.66
  • Revenue Growth
  • AGX 45.08
  • STOK 2333.81
  • 52 Week Low
  • AGX $63.53
  • STOK $5.35
  • 52 Week High
  • AGX $246.60
  • STOK $16.15
  • Technical
  • Relative Strength Index (RSI)
  • AGX 46.52
  • STOK 67.00
  • Support Level
  • AGX $199.20
  • STOK $11.19
  • Resistance Level
  • AGX $214.00
  • STOK $12.00
  • Average True Range (ATR)
  • AGX 9.08
  • STOK 0.54
  • MACD
  • AGX -2.70
  • STOK -0.04
  • Stochastic Oscillator
  • AGX 29.35
  • STOK 75.30

About AGX Argan Inc.

Argan Inc is a United States-based construction firm that conducts operations through its wholly-owned subsidiaries, GPS, APC, TRC, and SMC. Through GPS and APC it provides a full range of engineering, procurement, construction, commissioning, maintenance, project development and technical consulting services to the power generation market, including the renewable energy sector, for a wide range of customers, including independent power project owners, public utilities, power plant heavy equipment suppliers and other commercial firms with power requirements in the U.S., Ireland and the U.K. It operates in three segments: Power Services, Industrial Services, and Telecom Services, out of which Power Services derives the majority of revenue.

About STOK Stoke Therapeutics Inc.

Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

Share on Social Networks: